Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
3.675
+0.065 (1.80%)
At close: Nov 4, 2024, 4:00 PM
3.580
-0.095 (-2.59%)
After-hours: Nov 4, 2024, 4:23 PM EST
Kiora Pharmaceuticals Employees
Kiora Pharmaceuticals had 12 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,335,000
Profits / Employee
$222,419
Market Cap
10.92M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Cutera | 430 |
PAVmed | 107 |
Turnstone Biologics | 80 |
Biora Therapeutics | 58 |
Vincerx Pharma | 42 |
Dominari Holdings | 28 |
BioRestorative Therapies | 11 |
Alterity Therapeutics | 10 |
KPRX News
- 6 days ago - Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Newsfile Corp
- 5 weeks ago - Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - Newsfile Corp
- 3 months ago - Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Newsfile Corp
- 3 months ago - Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile Corp
- 4 months ago - Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - Newsfile Corp
- 4 months ago - Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - Newsfile Corp
- 4 months ago - Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease - Newsfile Corp